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DUS = doppler ultrasound scan 
DVT = deep venous thrombosis 
ICU = intensive care unit 
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COVID-19, a viral respiratory illness caused by the severe acute respiratory syndrome 
coronavirus 2, may predispose patients to thrombotic disease, both in the venous and arterial 
circulations, due to excessive inflammation, platelet activation, endothelial dysfunction, and 
stasis.1  
Screening for venous thromboembolism (VTE) in hospitalized COVID-19 patients is 
challenging. On the one hand, one should avoid a surge in upper and/or lower vascular 
ultrasound studies to avoid unnecessary prolonged direct exposure of staff to infected patients, 
avoid the risk of transmission of COVID-19 between patients via sonographers and avoid 
unnecessary wastage of personal protective equipment (PPE).2 On the other hand, the incidence 
of VTE in critically-ill COVID-19 patients is high and standard clinical symptoms associated 
with lower or upper extremity thrombus, such as swelling and pain, are often difficult to assess 
in intubated patients.3 Therefore, timing, patient selection and VTE-scanning methods should 
be critically reassessed based on local availability of staff and PPE.  
 
Doppler Ultrasound Scan (DUS) 
 
i) On the general ward (non-ICU) 
Several studies report a lower incidence of VTE in COVID-19 patients hospitalized on a 
medical ward (ranging between 1.6-22.5%) as compared to intensive care unit (ICU)-patients 
(25%-100%).4, 5 Lerardi et al. report a deep venous thrombosis (DVT) incidence of 1.6% among 
60 non-ICU patients, routinely screened by doppler ultrasound.6 In a prospective study of 156 
non-ICU COVID-19 patients with D-dimer levels >1000 ng/ml, compression ultrasound 
screening for asymptomatic DVT showed an incidence of 14.7% (only one proximal DVT);7 
findings in line with another systematic screening for the diagnosis of deep vein thrombosis 
(DVT) by lower limb vein compression ultrasonography in 84 consecutive non-ICU patients 
despite uniform pharmacological thromboprophylaxis (incidence of 11.9%; 2.4% proximal 
DVT). Again, high D-dimer levels (>3000 µg/L) were indicative of the presence of 
asymptomatic VTE.8 In a retrospective cohort study of 71 non-ICU treated COVID-19 patients 
on anticoagulant thromboprophylaxis, who underwent systematic low limb venous duplex 
ultrasonography at hospital discharge or earlier if DVT was clinically suspected, 16 patients 
developed VTE (22.5%) and 7 PE (10%).9  
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ii) On the Intensive Care Unit (ICU) 
As previously mentioned, the incidence of DVT in critically-ill COVID-19 ICU patients is high, 
despite prophylactic anticoagulation strategies. A cross-sectional study in Wuhan, China in 48 
ICU patients on low molecular weight heparin (LMWH) thromboprophylaxis detected lower 
extremity DVTs in 41 patients (85.4%), with 36 (75%) isolated distal DVTs and 5 (10.4%) 
proximal DVT.10 In another retrospective study from Wuhan, all 88 ICU patients on LMWH 
thromboprophylaxis underwent compression ultrasonography. Here, the overall incidence of 
DVT was 46% (95% confidence interval [CI] 35–56%), comprising of proximal DVT in 9% 
(95% CI 3–15%) and distal DVT in 46% (95% CI 35–56%).11 Several other studies performed 
systematic DUS screening in COVID-19 ICU patients on prophylactical anticoagulation and 
report VTE incidences of 58,6% up to 100%12, 13 or DVT incidences of 65% (at admission; and 
79% 48 hours after admission),14 36%,15 37.3%16 and 46.1%3 respectively. Remarkably, 
Grandmaison et al. report a high VTE-incidence of 56% even in ICU patients receiving 
therapeutic anticoagulation.12 A recent systematic review of 28 studies including a total of 2,928 
patients with COVID-19 found that thrombotic complications were reported in 34% of ICU-
managed patients, with DVT in 16.1% and PE in 12.6% of patients, despite anticoagulant 
thromboprophylaxis.17 Studies adopting systematic screening for VTE with Duplex ultrasound 
reported a significantly higher incidence of venous thrombosis on the ICU compared to those 
relying on clinical suspicion (56.3% vs. 11.0%, p < 0.001).17  
 
 
iii) Timing and patient selection for Doppler ultrasound 
There is no clear guidance on how screening for VTE in COVID-19 patients should be 
organized. Some centres perform routine DUS in every hospitalized patient,12 some centres 
only in critically-ill patients6 and others only when VTE-symptoms are present. In a study of 
patients on 2 French ICUs, where DUS is performed as a standard of care, the overall VTE 
incidence was reported to be 69%.13 As previously discussed, in their multi-centric 
retrospective study of 388 COVID-19 patients, Lodigiani et al. reported a VTE incidence of 
27.6% in the ICU without systematic ultrasound screening.18 This difference lends strong 
support to systematic screening by DUS for COVID-19 patients on ICU. In another cohort 
study, all hospitalized (non-ICU and ICU) COVID-19 patients were screened with DUS on a 
single day (320 patients).12 Patients confirmed to have VTE were switched to therapeutic 
anticoagulation and followed by clinical evaluation and repeated DUS of the index venous 
thrombosis. Under therapeutic anticoagulation, they did not observe any extension of 
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thrombosis or new symptomatic events. Davis et al. state that an ultrasound in patients with 
clinical suspicion of lower or upper limb DVT should only be considered in patients with high 
bleeding score (VTE-BLEED score),19 otherwise therapeutic anticoagulation should be started 
based on clinical findings20 or based on the correlation with respiratory and/or laboratory 
parameters (fraction of inspired oxygen, P/F ratio, respiratory rate, heparin administration, D-
dimer > 4000 ng/ml, IL-6, high ferritin or CRP), conditions mainly affecting patients on ICU.6 
Whilst some papers discourage routine screening for VTE by DUS on regular wards in 
asymptomatic or less sick patients,6 others select patients for screening based on the VTE-
BLEED score,21 dependent on the D-dimer level (> 3 x upper limit of normal or >4000 ng/mL)2 
or based on the (modified) Wells score. However, D-dimer is not so useful in the COVID-19 
cohort due to frequent marked baseline levels observed in patients with COVID-19 sepsis.22 
Nevertheless, a negative Wells score or Wells score below 2 should be reassuring, negating the 
need for additional imaging.21  
 
iv) Doppler ultrasound scanning methods 
 
Prolonged exposure of vascular sonographers to patients with COVID-19 should be carefully 
considered and balanced against the risks to staff and available resources, including staffing 
and PPE.2, 21  Local scanning protocols should be re-evaluated to minimize the scanning time 
and thus exposure per patient. In one study, direct communication between physicians resulted 
in cancellation or deferral of 72% of requested examinations in COVID-19-positive patients. 
Preserving DUS screening for patients with D-dimer >4000 ng/mL resulted in a significant 
(50%) decrease in the scan time (P < 0.0001) in comparison with conventional protocol.2 
A routine four limbs and neck compression duplex ultrasound should be sufficient to diagnose 
the majority of DVTs with minimal exposure time; when high clinical suspicion arises, a more 
focused scan at the site of the swelling can be obtained.12 If available, wireless ultrasound 
probes, covered in single use transparent films should be used to minimise the risk of viral 
contamination.23 
 
Computerised tomography (CT) 
 
Patients with COVID-19 have been shown to have an increased risk of pulmonary thrombosis 
and CT is the optimal modality to assess this. CT studies have shown that pulmonary 
thromboembolism in COVID-19 involves mainly the segmental and sub-segmental arteries of 
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segments affected by consolidation and may represent pulmonary artery thrombosis due to 
severe lung inflammation and hypercoagulability rather than thromboembolism. Pulmonary 
thrombosis or thromboembolism is best detected with CT pulmonary angiography (CTPA). 
Amongst patients with COVID-19, the yield of CTPA for pulmonary thromboembolism is 
around 38 %.24, 25  
In the majority of patients with evidence of pulmonary thromboembolism, the most proximal 
PE was in a segmental artery in 70% of patients, and the most proximal PE was located in the 
main/lobar pulmonary artery in 17% of patients,26 with similar distributions reported by 
others.27  
 
A number of studies have assessed the usefulness of CT scanning to diagnose VTE in patients 
with COVID-19, both in hospitalised patients on the general wards and inpatients on the 
intensive care unit (ICU). Since the prevalence of PE relates to the severity of the COVID-19 
infection, most studies report on the usefulness and yield of CTPA in patients on the ICU. 
However, data from a single-centre retrospective review of all CTPA studies in patients with 
suspected or confirmed COVID-19 showed that in 1,477 patients, 214 CTPA scans were 
performed, of which 84% were requested outside of the critical care setting. The overall 
proportion of PE in patients with COVID-19 was 5.4%. Amongst patients with a Wells score 
of ≥4 (‘PE likely’), 25% had PE and 25% did not. D-dimer was higher in patients with PE than 
without PE (median 8000 ng/mL; interquartile range [IQR] 4665–8000 ng/mL vs. 2060 ng/mL, 
IQR 1210–4410 ng/mL, P < 0.001). In the ‘low probability’ group, D-dimer was higher (P < 
0.001) in those with PE but had a limited role in excluding PE. Of all the patients with PE on 
CTPA, 66% were outside the ICU and nearly half of PE events were diagnosed on hospital 
admission.25 This is surprising because it is known that the risk of VTE increases with the 
duration of hospitalisation. In a single-centre cross-sectional study, all 70 patients hospitalized 
for more than 5 days in with COVID-19 pneumonia and treated with standard anticoagulant 
thromboprophylaxis, underwent 2-point compressive ultrasound assessment of the leg vein 
system. Asymptomatic DVT was identified in 9 (13.6%) patients and CTPA detected PE in five 
patients.28 
i) On the intensive care unit 
Whilst in all-comers hospitalised with COVID-19, the prevalence of PE on CTCA was 5.4%,25, 
29, 30 the yield of CTCA for PE ranges from 34-100% amongst patients on the ICU. In a 
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retrospective review of 92 patients with ARDS on the ICU, 26 of the patients underwent CTPA 
and PE was detected in 16 patients, showing that CTPA had 62% yield for PE in this cohort. 
When present, PE was unilateral in 81% and bilateral in 19% of patients. The most proximal 
thrombus was localized in main (25%), lobar (12%) or segmental (63%) pulmonary artery. 
Most of the thrombi (81%) were located in a parenchymatous condensation. Only 19% of 
patients with PE  on CT had lower limb DVT on Doppler ultrasound.27 A couple of studies have 
reported on cohorts with COVID-19 on the ICU in whom routine CT scanning was performed. 
In an observational study of 39 consecutive mechanically-ventilated patients, of whom 51% 
received ECMO, all patients were scanned in a dedicated COVID-19 CT suite and PE was 
detected in 38.5% of patients.30 In another single-centre study of 72 consecutive COVID-19 
patients admitted to ICU with acquired respiratory distress syndrome, CT angiography of the 
thorax, abdomen and pelvis were performed on admission according to routine institutional 
protocol, with further imaging as clinically indicated. Some 58% of patients were diagnosed on 
CT to have thrombotic complications, comprising 47% of patients with pulmonary arterial 
thrombosis, 21% with peripheral venous thrombosis, and 7% with systemic arterial thromboses 
/ end-organ embolic complications. In those with pulmonary arterial thromboses, 93% were 
identified incidentally on first screening CT with only 7% suspected clinically. Biomarkers of 
coagulation including D-dimer, fibrinogen level, activated partial thromboplastin time or of 
inflammation (white cell count, C-reactive protein), did not discriminate between patients with 
or without thrombotic complications.31  
ii) In patients receiving extra-corporeal membrane oxygenation (ECMO) 
A retrospective observational analysis of 13 patients with ARDS requiring veno-venous 
ECMO, who all underwent CT, reported that 100% of the patients experienced venous 
thromboembolism, despite treatment with and close attention to anticoagulation. Ten patients 
had isolated cannula-associated DVT, two patients had isolated PE, and one patient had both 
cannula-associated DVT and PE. One patient had thrombotic occlusion of the centrifugal pump, 
and one had oxygenator thrombosis requiring circuit replacement.29  Another report assessing 
the CT thorax of all 51 patients receiving ECMO with COVID-19 pneumonitis in a single centre 
showed that majority of patients had areas of ischaemia within consolidated lungs, almost half 
of these without subtending pulmonary artery thrombosis. Some 35% had macroscopic 
thrombosis and 26% had ischaemia without associated thrombus.32 
iii) Usefulness of CT 
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It has been suggested that D-dimer should be used as a guide to indicate the likelihood of PE 
when no clinical features of PE are present.33 However, estimation of D- dimer levels for 
predicting thrombosis risk, whilst useful in patients presenting to hospital, is generally not 
helpful, given the significant baseline elevations in ICU-treated COVID-19 patients. The 
Report of the National Institute for Public Health of the Netherlands33 recommends that in 
patients with COVID-19 in whom there is a high clinical suspicion for PE, and in whom the D-
dimer level is elevated, CTPA should be considered. The D-dimer threshold used should follow 
locally used algorithms, that is, at least 500 µg/L with an age-adjusted threshold or 1000 µg/L 
or greater when no age criteria are present. In patients with a D-dimer <1000 µg/L on admission 
but a significant increase during hospital stay to levels higher than 2000–4000 µg/L, imaging 
for DVT or PE should be considered, in particular if they develop features indicative of 
thrombosis such as venous congestion and/or thrombosis on chest CT scans, clotting of 
extracorporeal circuits, or deterioration in clinical condition such as hypoxia or hypotension. 
In summary, CT is very useful modality to identify pulmonary thrombosis and embolism. The 
incidence of pulmonary thromboembolism increases with the severity of COVID-19 sepsis and 
so the yield of CTPA increases in the higher risk patients and in those on ICU, there should be 
a low threshold for requesting CTPA.  
Sublingual ultrasound 
COVID-19 is associated not only with macrovascular, but also microvascular thrombosis. A 
couple of small, exploratory studies have assessed the presence of sublingual microcirculatory 
and skin perfusion alterations in COVID-19 pneumonia. In a small prospective observational 
study of 27 mechanically ventilated patients with ARDS secondary to COVID-19, sublingual 
microcirculation was assessed by hand-held video microscopy with subsequent software-
assisted analysis of videos.34 Capillary refill time was prolonged, total and perfused vascular 
density were high; and the proportion of perfused vessels, microvascular flow index and red 
blood cell velocity were reduced. The proportion of perfused vessels was inversely correlated 
with total vascular density. These findings were indicative of microvascular thrombosis. In 
another small observational cohort study of 13 patients on the ICU, without clinical features of 
cardiogenic shock, in vivo evaluation of the sublingual microcirculation was performed using 
a handheld video capillaroscopy system with imaging analysed using the specialised software.35 
There was evidence of microvascular thrombosis in 11 patients (85%). Four patients (31%) 
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Pulmonary and venous thrombosis occur frequently in patients with COVID-19 and pulmonary 
thrombosis is frequently non-embolic. The prevalence increases in ICU patients and is very 
high in patients on ECMO. In patients outside of the ICU setting, D-dimer elevation on 
presentation or marked increase from baseline should alert the need for doppler ultrasound scan 
of the lower limbs. In the ICU setting, consideration should be given to routine screening with 
doppler ultrasound, given the high prevalence of thrombosis in this cohort in the setting of 
standard anticoagulant thromboprophylaxis, if the diagnosis would alter management. 
Pulmonary thromboembolism usually affects distal vasculature. Screening with CTCA is not 
justified in patients on the general wards, unless there are clinical features and/or marked 
elevations in markers of COVID-19-associated coagulopathy. However, the risk of PE in ICU 
patients is very high, and especially in patients on ECMO, where studies that employed routine 
screening have uncovered up to 100% incidence of pulmonary thrombosis despite standard 
anticoagulant thromboprophylaxis. This highlights the need for increased dose 
thromboprophylaxis in high-risk patients, if possible, and increased vigilance, with a low 
threshold for requesting CTPA and understanding that lack of lower limb thrombosis on 
ultrasound does not exclude pulmonary venous thrombosis. The logistics of CT scanning all 
ICU patients with COVID-19 in most centres without a dedicated co-located CT scanner makes 
this unfeasible, both in terms of infection risk and also the risk of transporting such critically ill 
patients across the hospital. Therefore, in patients with low bleeding risk and high clinical 
suspicion of VTE, the initiation of therapeutic anticoagulation without confirmation of VTE by 
imaging should be considered. However, since clinical features and D-dimer levels may not 
accurately reflect the occurrence of pulmonary thromboembolism, more data are needed to 
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Venous compression ultrasound in a 43-year-old male COVID-19 patient, requiring mechanical 
ventilation on the intensive care unit (left panel: before compression, right panel: during 
compression). The ultrasound reveals a large, semi-occlusive venous clot in the right common 
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